This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory



Bayer Announces Self-Infusion Training Program and FDA Approval of Larger Kogenate®FS Vial Size

Bayer HealthCare Pharmaceuticals recently announced the launch of a new self-infusion training program. BayCuff™ is an educational initiative designed to help hemophilia A patients and their caregivers learn intravenous infusion of recombinant factor VIII. The primary component of the program is an adjustable cuff worn on the hand or arm that allows patients to practice their technique without actually infusing themselves. It also helps caregivers learn to give home infusions on others.

“The idea for BayCuff was the result of 10 years of working with boys with hemophilia A and their families,” said Tessa Speller, RN, formerly of the Henry Ekert Hemophilia Centre, Royal Children’s Hospital, Melbourne, Australia, and inventor of BayCuff™. “For both parents and boys themselves, self-treatment brings the ultimate goal – independence. The BayCuff self-infusion training program allows them to address issues such as needle phobias, working with their non-dominant hand and using veins they have not used before.”

In a separate news release, the company announced that the U.S. Food and Drug Administration approved a 3,000 IU (international unit) vial size of Kogenate ®FS, a recombinant factor product manufactured by Bayer. The new vial size, according to Bayer, “offers greater convenience” to hemophilia A patients who require a higher dose of the product. It is expected to offer more precise dosing and eliminate the need for patients to combine smaller vials.

The availability of Kogenate® FS in a 3,000 IU vial demonstrates Bayer’s commitment to adolescent and adult patients, who are more likely to have a need for higher doses and who will appreciate the greater convenience of the larger vial,” said Joni Osip, RN, MS, Hemophilia Nurse Coordinator, Center for Bleeding and Clotting Disorders at the University of Minnesota Medical Center, Fairview, in Minneapolis.

Source: Bayer HealthCare news releases dated July 9 & August 7, 2009